Please assess the completion status of the following clinical trial:

Trial Title: Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Signed informed consent, release of medical information, and Health Insurance Portability and Accountability Act (HIPAA) documents~* Male, postmenopausal female, or female who may become pregnant but is using adequate contraceptive precautions (defined as use of oral contraceptive, intrauterine devices, surgical contraception, or a combination of a condom and a spermicide), with negative pregnancy test~* Admitted to the clinical center at the time of study entry~* Listed with United Network for Organ Sharing (UNOS) for cardiac transplantation~* Clinical indication and accepted candidate for implantation of an FDA approved LVAD as a bridge to transplantation~* Hemoglobin between 9.0 gm/dl and 16.1 gm/dl within 24 hours prior to study entry~* Platelet count between 100,000/ul and 450,000/ul within 24 hours prior to study entry~* White blood cell count between 2,500/ul and upper limit of normal within 24 hours prior to study entry~Exclusion Criteria~* Cardiothoracic surgery within 30 days prior to study entry~* Myocardial infarction within 6 months prior to study entry~* Prior cardiac transplantation, left ventricular (LV) reduction surgery, or cardiomyoplasty~* Acute reversible cause of heart failure (e.g., myocarditis, profound hypothyroidism)~* Anticipated requirement for biventricular mechanical support~* Stroke within 30 days prior to study entry~* Received investigational intervention within 30 days of study entry~* Pregnant or breastfeeding at time of study entry~* HIV positive within 30 days prior to study entry~* Active systemic infection within 48 hours prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Intramyocardial injection of bone marrow mononuclear cells + LVAD
- Group 2 (Type: EXPERIMENTAL): Intramyocardial injection of CD34+ selected bone marrow mononuclear cells + LVAD
- Group 3 (Type: OTHER): LVAD alone

Based on this trial design, predict the completion outcome and termination type (if applicable).